top of page
SABINA
MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN FOR PIK3CA/PTEN ALTERED METAPLASTIC BREAST CANCER
PIK3CA/PTEN altered metaplastic breast cancer
8
28
II
Spain
Recruitment
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE FOR COHORT A IS TO ASSESS THE EFFICACY OF THE COMBINATION OF MEN1611 WITH ERIBULIN AS DETERMINED BY CLINICAL BENEFIT RATE IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-KNOWN/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED METAPLASTIC BREAST CARCINOMA. THE PRIMARY OBJECTIVE FOR COHORT B IS TO ASSESS THE EFFICACY OF MEN1611 AS MONOTHERAPY AS DETERMINED BY THE OBJECTIVE RESPONSE RATE AT 6 WEEKS.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
PHERGAIN SITES
Instituto Valenciano de Oncología (Spain) | Hospital Universitario Virgen del Rocío (Spain) | Onkologikoa (Spain) | Hospital Universitario de Torrejón (Spain) | Hospital Universitario Clínico San Cecilio de Granada (Spain) | Institut Català d’ Oncologia L’Hospitalet (Spain) | Hospital Universitari Vall D'Hebron (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page